With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of ...

Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...

Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...

Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by anti-corruption authorities. | Eisai plans to lay off 121 employees in the U.

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

That includes GSK – which licensed a B7-H3 ADC from Hansoh Pharma in a $1.5 billion-plus ... MSD – known as Merck & Co in the US and Canada – acquired rights to HER3-directed ADC patritumab ...

Related News BOCOMI: AI Tech Drives New Opportunities in Pharma Sector; INNOVENT BIO/ HANSOH PHARMA/ SINO BIOPHARM/ Others Recommended At the same time, they will continue to improve relevant ...